Clinical and analytical considerations in the study of health status in device trials for heart failure

Sharon Lise T Normand, Thomas S. Rector, James D. Neaton, Ileana L. Pina, Ronald M. Lazar, Scott E. Proestel, Dina J. Fleischer, Jay N. Cohn, John A. Spertus

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Measures of health status (including symptoms, functional status, or quality of life) assess patients' experiences of their disease, and may therefore be used to quantify the benefits and risks of treatment. The aim of this article is to provide recommendations to regulatory agencies and research sponsors regarding the use of health status measures in medical device trials. Methods and Results: A workshop jointly planned by the Heart Failure Society of America and the US Food and Drug Administration was convened in October 2003 in Washington, DC. A Working Group to address health status measures initiated its collaboration at the workshop and continued its efforts throughout the next year. The Working Group recommended assessment of health status in all studies of heart failure therapy. Standardized instruments known to be valid, reliable, responsive to changes, and available in the languages of target populations should be used. Minimizing bias may be accomplished by using blinded, independent evaluators; collecting multiple health status measures; using valid statistical methods; and creating a health status resource bank. Conclusion: Assessment of health status should be part of any device trial and should occur regardless of whether the device is intended as destination or bridging therapy. Health status endpoints should be chosen, collected, and analyzed with the same level of scientific rigor as traditional clinical endpoints. Regulatory agencies should require use of analytic methods that handle the complexity of health status data in addition to usual protocol protections.

Original languageEnglish (US)
Pages (from-to)396-403
Number of pages8
JournalJournal of Cardiac Failure
Volume11
Issue number5 SPEC. ISS.
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Health Status
Heart Failure
Equipment and Supplies
Education
Health Resources
Health Services Needs and Demand
United States Food and Drug Administration
Language
Therapeutics
Quality of Life
Research

Keywords

  • Design
  • Endpoints
  • Quality of life
  • Regulatory

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Normand, S. L. T., Rector, T. S., Neaton, J. D., Pina, I. L., Lazar, R. M., Proestel, S. E., ... Spertus, J. A. (2005). Clinical and analytical considerations in the study of health status in device trials for heart failure. Journal of Cardiac Failure, 11(5 SPEC. ISS.), 396-403. https://doi.org/10.1016/j.cardfail.2005.04.002

Clinical and analytical considerations in the study of health status in device trials for heart failure. / Normand, Sharon Lise T; Rector, Thomas S.; Neaton, James D.; Pina, Ileana L.; Lazar, Ronald M.; Proestel, Scott E.; Fleischer, Dina J.; Cohn, Jay N.; Spertus, John A.

In: Journal of Cardiac Failure, Vol. 11, No. 5 SPEC. ISS., 06.2005, p. 396-403.

Research output: Contribution to journalArticle

Normand, SLT, Rector, TS, Neaton, JD, Pina, IL, Lazar, RM, Proestel, SE, Fleischer, DJ, Cohn, JN & Spertus, JA 2005, 'Clinical and analytical considerations in the study of health status in device trials for heart failure', Journal of Cardiac Failure, vol. 11, no. 5 SPEC. ISS., pp. 396-403. https://doi.org/10.1016/j.cardfail.2005.04.002
Normand, Sharon Lise T ; Rector, Thomas S. ; Neaton, James D. ; Pina, Ileana L. ; Lazar, Ronald M. ; Proestel, Scott E. ; Fleischer, Dina J. ; Cohn, Jay N. ; Spertus, John A. / Clinical and analytical considerations in the study of health status in device trials for heart failure. In: Journal of Cardiac Failure. 2005 ; Vol. 11, No. 5 SPEC. ISS. pp. 396-403.
@article{9c79732fa53d478ba948c8fce5b4cb25,
title = "Clinical and analytical considerations in the study of health status in device trials for heart failure",
abstract = "Background: Measures of health status (including symptoms, functional status, or quality of life) assess patients' experiences of their disease, and may therefore be used to quantify the benefits and risks of treatment. The aim of this article is to provide recommendations to regulatory agencies and research sponsors regarding the use of health status measures in medical device trials. Methods and Results: A workshop jointly planned by the Heart Failure Society of America and the US Food and Drug Administration was convened in October 2003 in Washington, DC. A Working Group to address health status measures initiated its collaboration at the workshop and continued its efforts throughout the next year. The Working Group recommended assessment of health status in all studies of heart failure therapy. Standardized instruments known to be valid, reliable, responsive to changes, and available in the languages of target populations should be used. Minimizing bias may be accomplished by using blinded, independent evaluators; collecting multiple health status measures; using valid statistical methods; and creating a health status resource bank. Conclusion: Assessment of health status should be part of any device trial and should occur regardless of whether the device is intended as destination or bridging therapy. Health status endpoints should be chosen, collected, and analyzed with the same level of scientific rigor as traditional clinical endpoints. Regulatory agencies should require use of analytic methods that handle the complexity of health status data in addition to usual protocol protections.",
keywords = "Design, Endpoints, Quality of life, Regulatory",
author = "Normand, {Sharon Lise T} and Rector, {Thomas S.} and Neaton, {James D.} and Pina, {Ileana L.} and Lazar, {Ronald M.} and Proestel, {Scott E.} and Fleischer, {Dina J.} and Cohn, {Jay N.} and Spertus, {John A.}",
year = "2005",
month = "6",
doi = "10.1016/j.cardfail.2005.04.002",
language = "English (US)",
volume = "11",
pages = "396--403",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "5 SPEC. ISS.",

}

TY - JOUR

T1 - Clinical and analytical considerations in the study of health status in device trials for heart failure

AU - Normand, Sharon Lise T

AU - Rector, Thomas S.

AU - Neaton, James D.

AU - Pina, Ileana L.

AU - Lazar, Ronald M.

AU - Proestel, Scott E.

AU - Fleischer, Dina J.

AU - Cohn, Jay N.

AU - Spertus, John A.

PY - 2005/6

Y1 - 2005/6

N2 - Background: Measures of health status (including symptoms, functional status, or quality of life) assess patients' experiences of their disease, and may therefore be used to quantify the benefits and risks of treatment. The aim of this article is to provide recommendations to regulatory agencies and research sponsors regarding the use of health status measures in medical device trials. Methods and Results: A workshop jointly planned by the Heart Failure Society of America and the US Food and Drug Administration was convened in October 2003 in Washington, DC. A Working Group to address health status measures initiated its collaboration at the workshop and continued its efforts throughout the next year. The Working Group recommended assessment of health status in all studies of heart failure therapy. Standardized instruments known to be valid, reliable, responsive to changes, and available in the languages of target populations should be used. Minimizing bias may be accomplished by using blinded, independent evaluators; collecting multiple health status measures; using valid statistical methods; and creating a health status resource bank. Conclusion: Assessment of health status should be part of any device trial and should occur regardless of whether the device is intended as destination or bridging therapy. Health status endpoints should be chosen, collected, and analyzed with the same level of scientific rigor as traditional clinical endpoints. Regulatory agencies should require use of analytic methods that handle the complexity of health status data in addition to usual protocol protections.

AB - Background: Measures of health status (including symptoms, functional status, or quality of life) assess patients' experiences of their disease, and may therefore be used to quantify the benefits and risks of treatment. The aim of this article is to provide recommendations to regulatory agencies and research sponsors regarding the use of health status measures in medical device trials. Methods and Results: A workshop jointly planned by the Heart Failure Society of America and the US Food and Drug Administration was convened in October 2003 in Washington, DC. A Working Group to address health status measures initiated its collaboration at the workshop and continued its efforts throughout the next year. The Working Group recommended assessment of health status in all studies of heart failure therapy. Standardized instruments known to be valid, reliable, responsive to changes, and available in the languages of target populations should be used. Minimizing bias may be accomplished by using blinded, independent evaluators; collecting multiple health status measures; using valid statistical methods; and creating a health status resource bank. Conclusion: Assessment of health status should be part of any device trial and should occur regardless of whether the device is intended as destination or bridging therapy. Health status endpoints should be chosen, collected, and analyzed with the same level of scientific rigor as traditional clinical endpoints. Regulatory agencies should require use of analytic methods that handle the complexity of health status data in addition to usual protocol protections.

KW - Design

KW - Endpoints

KW - Quality of life

KW - Regulatory

UR - http://www.scopus.com/inward/record.url?scp=20444423366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444423366&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2005.04.002

DO - 10.1016/j.cardfail.2005.04.002

M3 - Article

VL - 11

SP - 396

EP - 403

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 5 SPEC. ISS.

ER -